Background
- Oncogenic gene fusions are rare but clinically relevant events in melanoma, often activating MAPK signaling in the absence of canonical BRAF, NRAS, or NF1 mutations.
- The spectrum, co-mutational landscape, and clinical outcomes of such fusions in unselected melanoma cohorts remain incompletely defined.